Drawing for IBECTA

USPTO serial 85621838

IBECTA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BAKER, JORDAN A
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with IBECTA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

MAURY M. TEPPER, III TEPPER & EYSTER, PLLC3724 BENSON DRRALEIGH, NC 27609-7321UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in dermatology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, anti-infectivesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 1, 2015MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 1, 2015ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 31, 2014EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 30, 2014EX4GSOU EXTENSION 4 GRANTED—
Oct 28, 2014EXT4SOU EXTENSION 4 FILED—
Oct 28, 2014EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 22, 2014EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 21, 2014EX3GSOU EXTENSION 3 GRANTED—
Apr 16, 2014EXT3SOU EXTENSION 3 FILED—
Apr 16, 2014EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 22, 2013EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 21, 2013EX2GSOU EXTENSION 2 GRANTED—
Oct 14, 2013EXT2SOU EXTENSION 2 FILED—
Oct 14, 2013EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 24, 2013EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 23, 2013EX1GSOU EXTENSION 1 GRANTED—
Apr 22, 2013AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 1, 2013EXT1SOU EXTENSION 1 FILED—
Apr 1, 2013EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 30, 2012NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 4, 2012NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 4, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 15, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 23, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 23, 2012DOCKASSIGNED TO EXAMINER—
May 17, 2012MPMKNOTICE OF PSEUDO MARK MAILED—
May 16, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 14, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance